Key facts
- Notable investors include CAS Star, Innoangel Fund, Hefei Haiheng Innovation Investment, Jiangsu Jicui Molecular Engineering Research Institute, Qihang Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Lingxin Borui Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Lingxin Borui Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lingxin Borui Biotechnology
Manufacturer of life science and biotechnology solutions aims to support biomedical research and pharmaceutical innovation. The company's offerings feature custom reagents, diagnostic assay kits, and integrated laboratory service platforms, helping research institutions, biotech firms, and clinical laboratories access reliable experimental tools, accurate testing workflows, and scalable support services, enabling efficient translation of scientific discovery into commercial and clinical applications.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2022
- Website
- linxcell.cn/
- Ownership
- Privately Held (backing)
Lingxin Borui Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lingxin Borui Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lingxin Borui Biotechnology in its N-PORT filings yet. We sweep new filings monthly.